厄洛替尼治疗晚期非小细胞肺癌临床研究  

Erlotinib treatment of advanced non-small cell lung cancer clinical research

作　　者：黄惠燕[1] 林沛亮[2] 李云和[2] 

机构地区：[1]广东省医学科学院 广东省人民医院药学部,广东广州510120 [2]中山大学附属肿瘤医院药剂科,广东广州510000

出　　处：《中国医药科学》2014年第1期82-84,共3页China Medicine And Pharmacy

摘　　要：目的分析在晚期非小细胞肺癌的临床治疗中应用厄洛替尼的临床疗效、毒副反应等。方法从2009年4月～2013年4月期间收治的晚期非小细胞肺癌患者中选取30例作为研究对象，并给予患者应用厄洛替尼进行治疗，若患者出现病变进展、无法耐受的毒副反应，则终止治疗，期间观察患者在应用该药物后的疗效、毒副反应等。结果研究发现，30例晚期非小细胞肺癌患者，11例患者疾病进展（PD），12例患者疾病稳定（SD），7例患者部分缓解（PR），0例患者完全缓解（CR），治疗有效例数为7例，占总人数的23．33％。在毒副反应方面，患者在用药后，主要有恶心呕吐、腹泻、皮肤瘙痒以及皮疹等，程度均不严重，通过相应的治疗后得到缓解。结论在晚期非小细胞肺癌患者的临床治疗中应用厄洛替尼，有明显的疗效，且毒副反应较为轻微。Objective To analyze the clinical treatment of advanced non-small cell lung cancer in the application for it＇s clinical curative effect, adverse reaction and so on. Methods from April 2009 to April 2009 in patients with advanced non-small cell lung cancer treated during selecting 30 cases as the research object, and to give patients used it for treatment,if patients lesions appears on the horizon,can＇t tolerate the side reaction of, end treatment,after the application of the drug were observed during the period of efficacy,adverse reaction,etc. Results The study found that 30 cases of advanced non-small cell lung cancer patients,11 patients with disease progression （PD）,12 patients had stable disease （SD）,7 cases of patients with partial response （PR）,and 0 cases with complete remission （CR）,effective treatment cases in 7 cases,accounting for 23.33% of the total. In terms of adverse reactions,patients after medication,there are mainly nausea and vomiting,diarrhea,itching and rash,etc.,were serious degree,through the appropriate ease after treatment. Conclusion In the clinical treatment of patients with advanced non-small cell lung cancer in the application,for it has obvious curative effect,and side reaction was mild.

关 键 词：厄洛替尼 晚期非小细胞肺癌 疗效 毒副反应 

分 类 号：R734.2[医药卫生—肿瘤]